A phase 1 study of AX-5006 for Parkinson's Disease
Latest Information Update: 22 Jun 2023
Price :
$35 *
At a glance
- Drugs AB 5006 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 22 Jun 2023 New trial record
- 20 Jun 2023 According to Axial Therapeutics media release , company has received a research grant from The Michael J. Fox Foundation for Parkinsons Research through its Therapeutic Pipeline Program.
- 20 Jun 2023 According to Axial Therapeutics media release company is planning to initiate this study in 2024.